Literature DB >> 2381266

Levels of acarboxy prothrombin (PIVKA-II) and coagulation factors in warfarin-treated patients.

S Umeki1, Y Umeki.   

Abstract

PIVKA-II (protein induced by vitamin K absence or antagonists-II) was determined and compared with other coagulation factors in normal subjects and patients treated with the anticoagulant warfarin. In 18 (60%) of 30 patients treated with warfarin, PIVKA-II values were 1 microgram/ml or more, although they were less than 1 microgram/ml in all 39 normal subjects (100%). In patients treated with warfarin, values of prothrombin time and partial thromboplastin time were significantly higher than those in normal subjects. However, values of hepaplastintest (normotest) and thrombotest in the patients were greatly lower than those in normal subjects. There were no significant differences between bleeding time or plasma fibrinogen values in the patients and normal subjects. The values of PIVKA-II were inversely correlated (P less than 0.01) with those of hepaplastintest and thrombotest. The measurement of PIVKA-II in the plasma should be useful in detecting vitamin K-deficient status among haemorrhagic disorders.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381266

Source DB:  PubMed          Journal:  Med Lab Sci        ISSN: 0308-3616


  3 in total

1.  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

Authors:  Nita A Limdi; Thomas D Nolin; Sarah L Booth; Amanda Centi; Marisa B Marques; Michael R Crowley; Michael Allon; T Mark Beasley
Journal:  Am J Kidney Dis       Date:  2014-11-25       Impact factor: 8.860

2.  The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.

Authors:  Keun Hee Kang; Ji Hoon Kim; Seong Hee Kang; Beom Jae Lee; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Jong Jae Park; Jae Seon Kim; Young Tae Bak; Kwan Soo Byun
Journal:  Gut Liver       Date:  2015-03       Impact factor: 4.519

3.  The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.

Authors:  Jun Ji; Lijuan Liu; Feifei Jiang; Xue Wen; Yu Zhang; Shengcong Li; Jinli Lou; Ying Wang; Ning Liu; Qiuyan Guo; Yongmei Jia; Chunfang Gao
Journal:  J Clin Lab Anal       Date:  2021-09-30       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.